nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

13.04.2020 | Original Article – Cancer Research

Germline APOBEC3B deletion influences clinicopathological parameters in luminal-A breast cancer: evidences from a southern Brazilian cohort

verfasst von: Glauco Akelinghton Freire Vitiello, Nathalia de Sousa Pereira, Marla Karine Amarante, Bruna Karina Banin-Hirata, Clodoaldo Zago Campos, Karen Brajão de Oliveira, Roberta Losi-Guembarovski, Maria Angelica Ehara Watanabe

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 6/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

APOBEC3A and APOBEC3B cytidine deaminases have been implicated in the pathogenesis of multiple cancers, including breast cancer (BC). A germline deletion linking APOBEC3A and APOBEC3B loci (A3A/B) has been associated with higher APOBEC-mediated mutational burden, but its association with BC risk have been controversial. Therefore, this study investigated the association between A3A/B and BC susceptibility and clinical presentation in a Brazilian cohort.

Methods

A3A/B deletion was evaluated through allele-specific PCR in 341 BC patients and 397 women without familial or personal history of neoplasia from Brazil and associations with susceptibility to BC subtypes were tested through age-adjusted logistic models while correlations with clinicopathological parameters were tested using Kendall’s tests.

Results

No association was found between A3A/B and BC susceptibility; however, in Luminal-A BCs, it was positively correlated with tumor size (Tau-c = 0.125) and Ki67 (Tau-c = 0.116) and negatively correlated with lymph node metastasis (LNM) (Tau-c = − 0.162). The negative association between A3A/B with LNM in Luminal-A BCs remained significant even after adjusting for tumor size and Ki67 in logistic models (OR = 0.22; p = 0.008).

Conclusion

These results show that although A3A/B may not modify BC susceptibility in Brazilian population, it may affect clinicopathological features in BC subtypes, promoting tumor cell proliferation while being negatively associated with LNM in Luminal-A BCs.

Burns MB et al (2013) APOBEC3B is an enzymatic source of mutation in breast cancer. Nature 494:366–370. https://doi.org/10.1038/nature11881 CrossRefPubMedPubMedCentral

Burns MB, Temiz NA, Harris RS (2013) Evidence for APOBEC3B mutagenesis in multiple human cancers. Nat Genet 45:977–983. https://doi.org/10.1038/ng.2701 CrossRefPubMedPubMedCentral

Burns MB, Leonard B, Harris RS (2015) APOBEC3B: pathological consequences of an innate immune DNA mutator. Biomed J 38:102–110. https://doi.org/10.4103/2319-4170.148904 CrossRefPubMed

Cann HM (2002) A Human Genome Diversity Cell Line Panel. Science 296:261b–262. https://doi.org/10.1126/science.296.5566.261b CrossRef

Caval V, Suspène R, Shapira M, Vartanian J-P, Wain-Hobson S (2014) A prevalent cancer susceptibility APOBEC3A hybrid allele bearing APOBEC3B 3′UTR enhances chromosomal DNA damage. Nat Commun. https://doi.org/10.1038/ncomms6129 CrossRefPubMed

Cescon DW, Haibe-Kains B, Mak TW (2015) APOBEC3Bexpression in breast cancer reflects cellular proliferation, while a deletion polymorphism is associated with immune activation. Proc Natl Acad Sci 112:2841–2846. https://doi.org/10.1073/pnas.1424869112 CrossRefPubMed

Chan K et al (2015) An APOBEC3A hypermutation signature is distinguishable from the signature of background mutagenesis by APOBEC3B in human cancers. Nat Genet 47:1067–1072. https://doi.org/10.1038/ng.3378 CrossRefPubMedPubMedCentral

Chen Z et al (2019) Integrative genomic analyses of APOBEC-mutational signature, expression and germline deletion of APOBEC3 genes, and immunogenicity in multiple cancer types. BMC Med Genomics 12:131. https://doi.org/10.1186/s12920-019-0579-3 CrossRefPubMedPubMedCentral

Driscoll CB et al (2020) APOBEC3B-mediated corruption of the tumor cell immunopeptidome induces heteroclitic neoepitopes for cancer immunotherapy. Nat Commun. https://doi.org/10.1038/s41467-020-14568-7 CrossRefPubMedPubMedCentral

Gansmo LB, Romundstad P, Hveem K, Vatten L, Nik-Zainal S, Lønning PE, Knappskog S (2018) APOBEC3A/B deletion polymorphism and cancer risk. Carcinogenesis 39:118–124. https://doi.org/10.1093/carcin/bgx131 CrossRefPubMed

Göhler S et al (2015) Impact of functional germline variants and a deletion polymorphism in APOBEC3A and APOBEC3B on breast cancer risk and survival in a Swedish study population. J Cancer Res Clin Oncol 142:273–276. https://doi.org/10.1007/s00432-015-2038-7 CrossRefPubMed

Hashemi M, Moazeni-Roodi A, Taheri M (2019) Association of APOBEC3 deletion with cancer risk: a meta-analysis of 26225 cases and 37 201 controls Asia-Pacific. J Clin Oncol. https://doi.org/10.1111/ajco.13107 CrossRef

Henderson S, Fenton T (2015) APOBEC3 genes: retroviral restriction factors to cancer drivers. Trends Mol Med 21:274–284. https://doi.org/10.1016/j.molmed.2015.02.007 CrossRefPubMed

Kanu N et al (2016) DNA replication stress mediates APOBEC3 family mutagenesis in breast cancer. Genome Biol. https://doi.org/10.1186/s13059-016-1042-9 CrossRefPubMedPubMedCentral

Kehdy FS et al (2015) Origin and dynamics of admixture in Brazilians and its effect on the pattern of deleterious mutations. Proc Natl Acad Sci USA 112:8696–8701. https://doi.org/10.1073/pnas.1504447112 CrossRefPubMed

Kidd JM, Newman TL, Tuzun E, Kaul R, Eichler EE (2007) Population stratification of a common APOBEC gene deletion polymorphism. PLoS Genet 3:e63. https://doi.org/10.1371/journal.pgen.0030063 CrossRefPubMedPubMedCentral

Klonowska K et al (2017) The 30 kb deletion in the APOBEC3 cluster decreases APOBEC3A and APOBEC3B expression and creates a transcriptionally active hybrid gene but does not associate with breast cancer in the European population. Oncotarget. https://doi.org/10.18632/oncotarget.19400 CrossRefPubMedPubMedCentral

Law EK et al (2016) The DNA cytosine deaminase APOBEC3B promotes tamoxifen resistance in ER-positive breast cancer. Sci Adv 2:e1601737. https://doi.org/10.1126/sciadv.1601737 CrossRefPubMedPubMedCentral

Lins TC, Vieira RG, Abreu BS, Grattapaglia D, Pereira RW (2009) Genetic composition of Brazilian population samples based on a set of twenty-eight ancestry informative SNPs. Am J Hum Biol. https://doi.org/10.1002/ajhb.20976 CrossRef

Liu J et al (2016) The 29.5 kb APOBEC3B deletion polymorphism is not associated with clinical outcome of breast cancer. PLoS ONE 11:e0161731. https://doi.org/10.1371/journal.pone.0161731 CrossRefPubMedPubMedCentral

Long J et al (2013) A common deletion in the APOBEC3 genes and breast cancer risk. J Natl Cancer Inst 105:573–579. https://doi.org/10.1093/jnci/djt018 CrossRefPubMedPubMedCentral

Marouf C, Göhler S, Filho MIDS, Hajji O, Hemminki K, Nadifi S, Försti A (2016) Analysis of functional germline variants in APOBEC3 and driver genes on breast cancer risk in Moroccan study population. BMC Cancer. https://doi.org/10.1186/s12885-016-2210-8 CrossRefPubMedPubMedCentral

McCann JL, Klein MM, Leland EM, Law EK, Brown WL, Salamango DJ, Harris RS (2019) The DNA deaminase APOBEC3B interacts with the cell-cycle protein CDK4 and disrupts CDK4-mediated nuclear import of Cyclin D1. J Biol Chem 294:12099–12111. https://doi.org/10.1074/jbc.RA119.008443 CrossRefPubMed

Naslavsky MS et al (2017) Exomic variants of an elderly cohort of Brazilians in the ABraOM database. Hum Mutat 38:751–763. https://doi.org/10.1002/humu.23220 CrossRefPubMed

Nik-Zainal S et al (2012) Mutational processes molding the genomes of 21 breast cancers. Cell 149:979–993. https://doi.org/10.1016/j.cell.2012.04.024 CrossRefPubMedPubMedCentral

Nik-Zainal S et al (2014) Association of a germline copy number polymorphism of APOBEC3A and APOBEC3B with burden of putative APOBEC-dependent mutations in breast cancer. Nat Genet 46:487–491. https://doi.org/10.1038/ng.2955 CrossRefPubMedPubMedCentral

Okazaki IM, Hiai H, Kakazu N, Yamada S, Muramatsu M, Kinoshita K, Honjo T (2003) Constitutive expression of AID leads to tumorigenesis. J Exp Med 197:1173–1181. https://doi.org/10.1084/jem.20030275 CrossRefPubMedPubMedCentral

Parra FC, Amado RC, Lambertucci JR, Rocha J, Antunes CM, Pena SD (2003) Color and genomic ancestry in Brazilians. Proc Natl Acad Sci USA 100:177–182. https://doi.org/10.1073/pnas.0126614100 CrossRefPubMed

Pena SD, Bastos-Rodrigues L, Pimenta JR, Bydlowski SP (2009) DNA tests probe the genomic ancestry of Brazilians. Braz J Med Biol 42:870–876CrossRef

Periyasamy M et al (2015) APOBEC3B-mediated cytidine deamination is required for estrogen receptor action in breast cancer. Cell Rep 13:108–121. https://doi.org/10.1016/j.celrep.2015.08.066 CrossRefPubMedPubMedCentral

Pimenta JR et al (2006) Color and genomic ancestry in Brazilians: a study with forensic microsatellites. Hum Hered 62:190–195. https://doi.org/10.1159/000096872 CrossRefPubMed

Prat A et al (2015) Clinical implications of the intrinsic molecular subtypes of breast cancer. Breast 24(Suppl 2):S26–35. https://doi.org/10.1016/j.breast.2015.07.008 CrossRefPubMed

Ramiro AR et al (2004) AID is required for c-myc/IgH chromosome translocations in vivo. Cell 118:431–438. https://doi.org/10.1016/j.cell.2004.08.006 CrossRefPubMed

Revathidevi S et al (2016) Analysis of APOBEC3A/3B germline deletion polymorphism in breast, cervical and oral cancers from South India and its impact on miRNA regulation. Tumor Biol 37:11983–11990. https://doi.org/10.1007/s13277-016-5064-4 CrossRef

Rezaei M, Hashemi M, Hashemi SM, Mashhadi MA, Taheri M (2015) APOBEC3 deletion is associated with breast cancer risk in a sample of Southeast Iranian population. Int J Mol Cell Med 4:103–108PubMedPubMedCentral

Roberts SA et al (2013) APOBEC3 deletion is associated with breast cancer risk in a sample of Southeast Iranian population. Nat Genet 45:970–976. https://doi.org/10.1038/ng.2702 CrossRefPubMedPubMedCentral

Sieuwerts AM et al (2014) Elevated APOBEC3B correlates with poor outcomes for estrogen-receptor-positive breast cancers. Hormones Cancer 5:405–413. https://doi.org/10.1007/s12672-014-0196-8 CrossRefPubMedPubMedCentral

Smid M et al (2016) Breast cancer genome and transcriptome integration implicates specific mutational signatures with immune cell infiltration. Nat Commun 7:12910. https://doi.org/10.1038/ncomms12910 CrossRefPubMedPubMedCentral

Sommer P, Mussil B, Suspène R, Aynaud M-M, Gauvrit A, Vartanian J-P, Wain-Hobson S (2013) Human APOBEC3A isoforms translocate to the nucleus and induce DNA double strand breaks leading to cell stress and death. PLoS ONE 8:e73641. https://doi.org/10.1371/journal.pone.0073641 CrossRef

Stephens P et al (2005) A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer. Nat Genet 37:590–592. https://doi.org/10.1038/ng1571 CrossRefPubMed

Tokunaga E et al (2016) Expression of APOBEC3B mRNA in primary breast cancer of Japanese women. PLoS ONE 11:e0168090. https://doi.org/10.1371/journal.pone.0168090 CrossRefPubMedPubMedCentral

Vitiello GAF, Amarante MK, Banin-Hirata BK, Campos CZ, de Oliveira KB, Losi-Guembarovski R, Watanabe MAE (2019) Transforming growth factor beta receptor II (TGFBR2) promoter region polymorphism in Brazilian breast cancer patients: association with susceptibility, clinicopathological features, and interaction with TGFB1 haplotypes. Breast Cancer Res Treat. https://doi.org/10.1007/s10549-019-05370-1 CrossRefPubMed

Vitiello GAF et al (2018) Transforming growth factor beta 1 (TGFbeta1) polymorphisms and haplotype structures have dual roles in breast cancer pathogenesis. J Cancer Res Clin Oncol 144:645–655. https://doi.org/10.1007/s00432-018-2585-9 CrossRefPubMed

Vitiello GAF, Losi Guembarovski R, Amarante MK, Ceribelli JR, Carmelo ECB, Watanabe MAE (2018) Interleukin 7 receptor alpha Thr244Ile genetic polymorphism is associated with susceptibility and prognostic markers in breast cancer subgroups. Cytokine 103:121–126. https://doi.org/10.1016/j.cyto.2017.09.019 CrossRefPubMed

Wen WX et al (2016) Germline APOBEC3B deletion is associated with breast cancer risk in an Asian multi-ethnic cohort and with immune cell presentation. Breast Cancer Res 18:56. https://doi.org/10.1186/s13058-016-0717-1 CrossRefPubMedPubMedCentral

Xuan D et al (2013) APOBEC3 deletion polymorphism is associated with breast cancer risk among women of European ancestry. Carcinogenesis 34:2240–2243. https://doi.org/10.1093/carcin/bgt185 CrossRefPubMedPubMedCentral

Yamanaka S et al (1995) Apolipoprotein B mRNA-editing protein induces hepatocellular carcinoma and dysplasia in transgenic animals. Proc Natl Acad Sci USA 92:8483–8487. https://doi.org/10.1073/pnas.92.18.8483 CrossRefPubMed

Titel: Germline APOBEC3B deletion influences clinicopathological parameters in luminal-A breast cancer: evidences from a southern Brazilian cohort
verfasst von: Glauco Akelinghton Freire Vitiello
Nathalia de Sousa Pereira
Marla Karine Amarante
Bruna Karina Banin-Hirata
Clodoaldo Zago Campos
Karen Brajão de Oliveira
Roberta Losi-Guembarovski
Maria Angelica Ehara Watanabe
Publikationsdatum: 13.04.2020
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 6/2020
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-020-03208-8

Neu im Fachgebiet Onkologie

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Germline APOBEC3B deletion influences clinicopathological parameters in luminal-A breast cancer: evidences from a southern Brazilian cohort

Abstract

Purpose

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2020

Proton therapy re-irradiation preserves health-related quality of life in large recurrent glioblastoma

Signaling pathways and clinical application of RASSF1A and SHOX2 in lung cancer

Attitude of cancer patients from online self-help groups towards physical activity

Can robotic-assisted radical cystectomy provide patients with a smaller trauma and faster recovery period? A systematic review and meta-analysis of comparative trials

Improved survival in metastatic breast cancer: results from a 20-year study involving 1033 women treated at a single comprehensive cancer center

Primary anatomical site as a prognostic factor for pleomorphic liposarcoma

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie